Investors > News Releases
Jan 22, 2020
Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer
Pipeline
Jan 21, 2020
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer
Pipeline
Jan 14, 2020
Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology
Corporate
Jan 06, 2020
Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference
Corporate
Jan 06, 2020
New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study
Products
Dec 30, 2019
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer
Pipeline
Dec 19, 2019
Myriad Genetics’ Board Member, S. Louise Phanstiel, Recognized by WomenInc. Magazine in 2019 List of Most Influential Corporate Directors
Corporate
Dec 14, 2019
Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes
Pipeline
Dec 04, 2019
Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening
Pipeline
Dec 03, 2019
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Products
Nov 21, 2019
Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients
Products
Nov 20, 2019
The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis
Pipeline
Nov 11, 2019
Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening
Pipeline
Nov 09, 2019
New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis
Pipeline
Nov 07, 2019
Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference
Corporate